On the recordJuly 11, 2017
My concern with the two bills we are considering today is that as drafted they would undermine public health, discourage pharmaceutical research, and undermine the FDA's central capacity to ensure medical products used on patients have demonstrated safety and efficiency.
Source
congress.gov




